Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dabrafenib and panitumumab with or without trametinib in BRAF V600E-mutant colorectal cancer
NL-OMON47621Phase 2Active, not recruiting
- Sponsor
- Novartis
- Start
- Sep 2013
- Modality
- Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of dabrafenib + trametinib, trametinib and panitumumab in colorectal cancer (CRC), sponsored by Novartis. Started Sep 2013; status: active, not recruiting.
02
Drugs
dabrafenib + trametinibtrametinibpanitumumab
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on NL-OMON47621.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON47621.